52
|
Duan WX, He MD, Mao L, Qian FH, Li YM, Pi HF, Liu C, Chen CH, Lu YH, Cao ZW, Zhang L, Yu ZP, Zhou Z. NiO nanoparticles induce apoptosis through repressing SIRT1 in human bronchial epithelial cells. Toxicol Appl Pharmacol 2015; 286:80-91. [PMID: 25840356 DOI: 10.1016/j.taap.2015.03.024] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2015] [Revised: 03/20/2015] [Accepted: 03/21/2015] [Indexed: 02/06/2023]
Abstract
With application of nano-sized nickel-containing particles (Nano-Ni) expanding, the health concerns about their adverse effects on the pulmonary system are increasing. However, the mechanisms for the pulmonary toxicity of these materials remain unclear. In the present study, we focused on the impacts of NiO nanoparticles (NiONPs) on sirtuin1 (SIRT1), a NAD-dependent deacetylase, and investigated whether SIRT1 was involved in NiONPs-induced apoptosis. Although the NiONPs tended to agglomerate in fluid medium, they still entered into the human bronchial epithelial cells (BEAS-2B) and released Ni(2+) inside the cells. NiONPs at doses of 5, 10, and 20μg/cm(2) inhibited the cell viability. NiONPs' produced cytotoxicity was demonstrated through an apoptotic process, indicated by increased numbers of Annexin V positive cells and caspase-3 activation. The expression of SIRT1 was markedly down-regulated by the NiONPs, accompanied by the hyperacetylation of p53 (tumor protein 53) and overexpression of Bax (Bcl-2-associated X protein). However, overexpression of SIRT1 through resveratrol treatment or transfection clearly attenuated the NiONPs-induced apoptosis and activation of p53 and Bax. Our results suggest that the repression of SIRT1 may underlie the NiONPs-induced apoptosis via p53 hyperacetylation and subsequent Bax activation. Because SIRT1 participates in multiple biologic processes by deacetylation of dozens of substrates, this knowledge of the impact of NiONPs on SIRT1 may lead to an improved understanding of the toxic mechanisms of Nano-Ni and provide a molecular target to antagonize Nano-Ni toxicity.
Collapse
Affiliation(s)
- Wei-Xia Duan
- Department of Occupational Health, Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Min-Di He
- Department of Occupational Health, Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Lin Mao
- Department of Occupational Health, Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Feng-Hua Qian
- Department of Hematology, Southwest Hospital, Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Yu-Ming Li
- Institute of Hepatobiliary Surgery, XinQiao Hospital, Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Hui-Feng Pi
- Department of Occupational Health, Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Chuan Liu
- Department of Occupational Health, Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Chun-Hai Chen
- Department of Occupational Health, Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Yong-Hui Lu
- Department of Occupational Health, Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Zheng-Wang Cao
- Department of Occupational Health, Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Lei Zhang
- Department of Occupational Health, Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Zheng-Ping Yu
- Department of Occupational Health, Third Military Medical University, Chongqing 400038, People's Republic of China
| | - Zhou Zhou
- Department of Occupational Health, Third Military Medical University, Chongqing 400038, People's Republic of China.
| |
Collapse
|
53
|
Dali-Youcef N, Froelich S, Moussallieh FM, Chibbaro S, Noël G, Namer IJ, Heikkinen S, Auwerx J. Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and 1H-HRMAS metabolomic profile in human gliomas. Sci Rep 2015; 5:9087. [PMID: 25791281 PMCID: PMC4367156 DOI: 10.1038/srep09087] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2014] [Accepted: 02/19/2015] [Indexed: 01/12/2023] Open
Abstract
Primary brain tumors are presently classified based on imaging and histopathological
techniques, which remains unsatisfaying. We profiled here by quantitative real time
PCR (qRT-PCR) the transcripts of eighteen histone deacetylases (HDACs) and a subset
of transcriptional co-factors in non-tumoral brain samples from 15 patients operated
for epilepsia and in brain tumor samples from 50 patients diagnosed with grade II
oligodendrogliomas (ODII, n = 9), grade III oligodendrogliomas (ODIII, n = 22) and
glioblastomas (GL, n = 19). Co-factor transcripts were significantly different in
tumors as compared to non-tumoral samples and distinguished different molecular
subgroups of brain tumors, regardless of tumor grade. Among all patients studied,
the expression of HDAC1 and HDAC3 was inversely correlated with
survival, whereas the expression of HDAC4, HDAC5, HDAC6,
HDAC11 and SIRT1 was significantly and positively correlated with
survival time of patients with gliomas. 1H-HRMAS technology revealed
metabolomically distinct groups according to the expression of HDAC1, HDAC4 and
SIRT1, suggesting that these genes may play an important role in regulating brain
tumorigenesis and cancer progression. Our study hence identified different molecular
fingerprints for subgroups of histopathologically similar brain tumors that may
enable the prediction of outcome based on the expression level of co-factor genes
and could allow customization of treatment.
Collapse
Affiliation(s)
- Nassim Dali-Youcef
- 1] Laboratoire de Biochimie et Biologie Moléculaire, Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, 1 place de l'hôpital, 67091 Strasbourg Cedex, France [2] Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)/CNRS UMR 7104/INSERM U 964/Université de Strasbourg, 1 rue Laurent Fries, 67404 Illkirch, France
| | - Sébastien Froelich
- Department of Neurosurgery, Hôpitaux Universitaires de Strasbourg, avenue Molière, 67085 Strasbourg Cedex, France
| | - François-Marie Moussallieh
- Department of Biophysics and Nuclear Medicine, Hôpitaux Universitaires de Strasbourg, CHU de Hautepierre, avenue Molière, 67200 Strasbourg Cedex, France
| | - Salvatore Chibbaro
- Department of Neurosurgery, Hôpitaux Universitaires de Strasbourg, avenue Molière, 67085 Strasbourg Cedex, France
| | - Georges Noël
- Centre Paul Strauss, 3 rue de la porte de l'Hôpital 67065 Strasbourg, Cedex, France
| | - Izzie J Namer
- Department of Biophysics and Nuclear Medicine, Hôpitaux Universitaires de Strasbourg, CHU de Hautepierre, avenue Molière, 67200 Strasbourg Cedex, France
| | - Sami Heikkinen
- Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)/CNRS UMR 7104/INSERM U 964/Université de Strasbourg, 1 rue Laurent Fries, 67404 Illkirch, France
| | - Johan Auwerx
- 1] Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)/CNRS UMR 7104/INSERM U 964/Université de Strasbourg, 1 rue Laurent Fries, 67404 Illkirch, France [2] Institut Clinique de la Souris, 1 rue Laurent Fries, 67404 Illkirch, France
| |
Collapse
|
56
|
Lee JS, Park JR, Kwon OS, Lee TH, Nakano I, Miyoshi H, Chun KH, Park MJ, Lee HJ, Kim SU, Cha HJ. SIRT1 is required for oncogenic transformation of neural stem cells and for the survival of "cancer cells with neural stemness" in a p53-dependent manner. Neuro Oncol 2014; 17:95-106. [PMID: 25096191 DOI: 10.1093/neuonc/nou145] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND Cancer stemness, observed in several types of glioma stem cells (GSCs), has been demonstrated to be an important barrier for efficient cancer therapy. We have previously reported that cancerous neural stem cells (F3.Ras.CNSCs), derived from immortalized human neural stem cells by a single oncogenic stimulation, form glial tumors in vivo. METHOD We searched for a commonly expressed stress modulator in both F3.Ras.CNSCs and GSCs and identified silent mating type information regulation 2, homolog (SIRT1) as a key factor in maintaining cancer stemness. RESULT We demonstrate that the expression of SIRT1, expressed in "cancer cells with neural stemness," is critical not only for the maintenance of stem cells, but also for oncogenic transformation. Interestingly, SIRT1 is essential for the survival and tumorigenicity of F3.Ras.CNSCs and GSCs but not for the U87 glioma cell line. CONCLUSION These results indicate that expression of SIRT1 in cancer cells with neural stemness plays an important role in suppressing p53-dependent tumor surveillance, the abrogation of which may be responsible not only for inducing oncogenic transformation but also for retaining the neural cancer stemness of the cells, suggesting that SIRT1 may be a putative therapeutic target in GSCs.
Collapse
Affiliation(s)
- Ji-Seon Lee
- Department of Life Sciences, Sogang University, Seoul, Korea (J.-S.L., J.-R.P., O.-S.K., H.-J.C.); Laboratory of Cancer and Stem Cell Biology, Sejong University, Seoul, Korea (T.-H.L.); Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, (I.N.); Subteam for Manipulation of Cell Fate, RIKEN BioResource Center, Wako, Japan (H.M.); Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea (K.-H.C.); Divisions of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (M.-J.P.); College of Medicine, Chung-Ang University, Seoul, Korea (H.J.L., S.U.K.); Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (H.J.L., S.U.K.)
| | - Jeong-Rak Park
- Department of Life Sciences, Sogang University, Seoul, Korea (J.-S.L., J.-R.P., O.-S.K., H.-J.C.); Laboratory of Cancer and Stem Cell Biology, Sejong University, Seoul, Korea (T.-H.L.); Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, (I.N.); Subteam for Manipulation of Cell Fate, RIKEN BioResource Center, Wako, Japan (H.M.); Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea (K.-H.C.); Divisions of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (M.-J.P.); College of Medicine, Chung-Ang University, Seoul, Korea (H.J.L., S.U.K.); Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (H.J.L., S.U.K.)
| | - Ok-Seon Kwon
- Department of Life Sciences, Sogang University, Seoul, Korea (J.-S.L., J.-R.P., O.-S.K., H.-J.C.); Laboratory of Cancer and Stem Cell Biology, Sejong University, Seoul, Korea (T.-H.L.); Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, (I.N.); Subteam for Manipulation of Cell Fate, RIKEN BioResource Center, Wako, Japan (H.M.); Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea (K.-H.C.); Divisions of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (M.-J.P.); College of Medicine, Chung-Ang University, Seoul, Korea (H.J.L., S.U.K.); Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (H.J.L., S.U.K.)
| | - Tae-Hee Lee
- Department of Life Sciences, Sogang University, Seoul, Korea (J.-S.L., J.-R.P., O.-S.K., H.-J.C.); Laboratory of Cancer and Stem Cell Biology, Sejong University, Seoul, Korea (T.-H.L.); Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, (I.N.); Subteam for Manipulation of Cell Fate, RIKEN BioResource Center, Wako, Japan (H.M.); Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea (K.-H.C.); Divisions of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (M.-J.P.); College of Medicine, Chung-Ang University, Seoul, Korea (H.J.L., S.U.K.); Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (H.J.L., S.U.K.)
| | - Ichiro Nakano
- Department of Life Sciences, Sogang University, Seoul, Korea (J.-S.L., J.-R.P., O.-S.K., H.-J.C.); Laboratory of Cancer and Stem Cell Biology, Sejong University, Seoul, Korea (T.-H.L.); Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, (I.N.); Subteam for Manipulation of Cell Fate, RIKEN BioResource Center, Wako, Japan (H.M.); Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea (K.-H.C.); Divisions of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (M.-J.P.); College of Medicine, Chung-Ang University, Seoul, Korea (H.J.L., S.U.K.); Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (H.J.L., S.U.K.)
| | - Hiroyuki Miyoshi
- Department of Life Sciences, Sogang University, Seoul, Korea (J.-S.L., J.-R.P., O.-S.K., H.-J.C.); Laboratory of Cancer and Stem Cell Biology, Sejong University, Seoul, Korea (T.-H.L.); Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, (I.N.); Subteam for Manipulation of Cell Fate, RIKEN BioResource Center, Wako, Japan (H.M.); Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea (K.-H.C.); Divisions of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (M.-J.P.); College of Medicine, Chung-Ang University, Seoul, Korea (H.J.L., S.U.K.); Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (H.J.L., S.U.K.)
| | - Kwang-Hoon Chun
- Department of Life Sciences, Sogang University, Seoul, Korea (J.-S.L., J.-R.P., O.-S.K., H.-J.C.); Laboratory of Cancer and Stem Cell Biology, Sejong University, Seoul, Korea (T.-H.L.); Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, (I.N.); Subteam for Manipulation of Cell Fate, RIKEN BioResource Center, Wako, Japan (H.M.); Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea (K.-H.C.); Divisions of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (M.-J.P.); College of Medicine, Chung-Ang University, Seoul, Korea (H.J.L., S.U.K.); Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (H.J.L., S.U.K.)
| | - Myung-Jin Park
- Department of Life Sciences, Sogang University, Seoul, Korea (J.-S.L., J.-R.P., O.-S.K., H.-J.C.); Laboratory of Cancer and Stem Cell Biology, Sejong University, Seoul, Korea (T.-H.L.); Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, (I.N.); Subteam for Manipulation of Cell Fate, RIKEN BioResource Center, Wako, Japan (H.M.); Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea (K.-H.C.); Divisions of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (M.-J.P.); College of Medicine, Chung-Ang University, Seoul, Korea (H.J.L., S.U.K.); Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (H.J.L., S.U.K.)
| | - Hong Jun Lee
- Department of Life Sciences, Sogang University, Seoul, Korea (J.-S.L., J.-R.P., O.-S.K., H.-J.C.); Laboratory of Cancer and Stem Cell Biology, Sejong University, Seoul, Korea (T.-H.L.); Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, (I.N.); Subteam for Manipulation of Cell Fate, RIKEN BioResource Center, Wako, Japan (H.M.); Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea (K.-H.C.); Divisions of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (M.-J.P.); College of Medicine, Chung-Ang University, Seoul, Korea (H.J.L., S.U.K.); Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (H.J.L., S.U.K.)
| | - Seung U Kim
- Department of Life Sciences, Sogang University, Seoul, Korea (J.-S.L., J.-R.P., O.-S.K., H.-J.C.); Laboratory of Cancer and Stem Cell Biology, Sejong University, Seoul, Korea (T.-H.L.); Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, (I.N.); Subteam for Manipulation of Cell Fate, RIKEN BioResource Center, Wako, Japan (H.M.); Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea (K.-H.C.); Divisions of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (M.-J.P.); College of Medicine, Chung-Ang University, Seoul, Korea (H.J.L., S.U.K.); Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (H.J.L., S.U.K.)
| | - Hyuk-Jin Cha
- Department of Life Sciences, Sogang University, Seoul, Korea (J.-S.L., J.-R.P., O.-S.K., H.-J.C.); Laboratory of Cancer and Stem Cell Biology, Sejong University, Seoul, Korea (T.-H.L.); Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, (I.N.); Subteam for Manipulation of Cell Fate, RIKEN BioResource Center, Wako, Japan (H.M.); Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea (K.-H.C.); Divisions of Radiation Cancer Research, Korea Institute of Radiological and Medical Sciences, Seoul, Korea (M.-J.P.); College of Medicine, Chung-Ang University, Seoul, Korea (H.J.L., S.U.K.); Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (H.J.L., S.U.K.)
| |
Collapse
|